Delivery Order SPE2DB20D1100-SPE2DB25FD5Z4
- Not listed
- The Defense Logistics Agency awarded a $1,143.89 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. The contract, which represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (valued at $999,999,999.00 through December 2026), is scheduled for completion by August 18, 2025. This delivery order was competitively awarded without...
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under the company's existing...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $1,525.20. This firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award represents a non-set-aside competitive procurement under the company's existing Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections. This is a firm fixed price, non-set-aside contract with a completion date of August 15, 2025, to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a delivery order valued at $4,411.39 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 14, 2025, with a completion date of August 15, 2025. This firm fixed-price delivery order represents a direct purchase of pharmaceutical inventory to support federal medical supply needs. The contract was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections with a ceiling value of $5,860.42. This is a firm fixed-price delivery order with an ultimate completion date of July 30, 2025, and represents a competitive award with no set-aside designation. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a $14,615.04 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 18, 2025, with completion scheduled for July 21, 2025. This contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections, with a ceiling value of $2,287.74. The award, issued on July 24, 2025, represents a firm fixed price delivery order with a completion date of July 25, 2025, indicating a short-duration, expedited fulfillment requirement. This contract was competitively awarded without set-aside designations, executed under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order valued at $10,641.96 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 21, 2025, with completion scheduled for August 22, 2025. The award represents a firm fixed price delivery order with no set-aside designation, indicating competitive selection. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, served as the prime contractor for this pharmaceutical supply delivery to support...
- The Defense Logistics Agency awarded a $37,571.53 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections. This delivery order, issued on August 1, 2025, with an ultimate completion date of August 4, 2025, represents a small-value pharmaceutical procurement under a larger indefinite delivery contract framework. The contract was competitively awarded with no set-aside designation, and performance will be executed from...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FD5Z4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pen injections, valued at $2,287.74, with a firm fixed price structure. The contract, awarded on July 23, 2025, with an ultimate completion date of July 24, 2025, is a non-set-aside competitive award with performance based in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement through the Defense Logistics Agency's Medical Supply Chain. The company's extensive portfolio with DLA includes delivery of brand-name and generic medications, vaccines, medical devices, and specialized healthcare commodities across multiple therapeutic domains to support military healthcare systems, the Defense Health Agency, U.S. Coast Guard, and other government healthcare entities. All of the company's reviewed contract awards have been non-set-aside and competitively awarded, demonstrating its capability to meet federal procurement requirements through open competition with pricing structures ranging from small-value transactions to orders exceeding $45,000.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 7/23/25 |